Role of non-genomic androgen signalling in suppressing proliferation of fibroblasts and fibrosarcoma cells

Cell Death and Disease

Volumn 5, Issue 12, 2014, Pages

  Castoria, G ^a   Giovannelli, P ^a   Di Donato, M ^a   Ciociola, A ^a   Hayashi, R ^b   Bernal, F ^b   Appella, E ^b   Auricchio, F ^a   Migliaccio, A ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ESTRADIOL; ESTROGEN RECEPTOR; FILAMIN A; PROGESTERONE RECEPTOR; PROTEIN P27; RAS PROTEIN; ANDROSTANOLONE; AR PROTEIN, HUMAN; CDKN1B PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DYRK KINASE; FILAMIN; METRIBOLONE; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; RAC1 PROTEIN; RAC1 PROTEIN, HUMAN; SERINE; TESTOSTERONE DERIVATIVE;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL CYCLE ARREST; CELL MIGRATION; DNA SYNTHESIS; FIBROBLAST; FIBROSARCOMA; IN VITRO STUDY; MESENCHYME CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; 3T3 CELL LINE; ANIMAL; CELL CYCLE CHECKPOINT; CELL MOTION; CELL PROLIFERATION; CYTOLOGY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MALE; MESENCHYMAL STROMA CELL; METABOLISM; MOUSE; PATHOLOGY; PHOSPHORYLATION; PROSTATE TUMOR; TUMOR CELL CULTURE;

ANIMALS; CELL CYCLE CHECKPOINTS; CELL MOVEMENT; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DIHYDROTESTOSTERONE; FIBROBLASTS; FIBROSARCOMA; FILAMINS; GENE EXPRESSION REGULATION; HUMANS; MALE; MESENCHYMAL STROMAL CELLS; METRIBOLONE; MICE; NIH 3T3 CELLS; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; RAC1 GTP-BINDING PROTEIN; RAS PROTEINS; RECEPTORS, ANDROGEN; SERINE; SIGNAL TRANSDUCTION; TESTOSTERONE CONGENERS; TUMOR CELLS, CULTURED;

EID: 84926639465     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.497     Document Type: Article

References (52)

1. Niu Y, Chang TM, Yeh S, Ma WL, Wang YZ, Chang C. Differential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails. Oncogene 2010; 29: 3593-3604.
2. Vander Griend DJ, Litvinov IV, Isaacs JT. Stabilizing androgen receptor in mitosis inhibits prostate cancer proliferation. Cell Cycle 2007; 6: 647-651.
3. Diaw L, Roth M, Schwinn DA, d'Alelio ME, Green LJ, Tangrea JA. Characteristics of a human prostate stromal cell line related to its use in a stromal-epithelial coculture model for the study of cancer chemoprevention. In Vitro Cell Dev Biol Anim 2005; 41: 142-148.
4. Sun X, He H, Xie Z, Qian W, Zhau HE, Chung LW et al. Matched pairs of human prostate stromal cells display differential tropic effects on LNCaP prostate cancer cells. In Vitro Cell Dev Biol Anim 2010; 46: 538-546.
5. Castoria G, Lombardi M, Barone MV, Bilancio A, Di Domenico M, Bottero D et al. Androgen-stimulated DNA synthesis and cytoskeletal changes in fibroblasts by a non-transcriptional receptor action. J Cell Biol 2003; 161: 547-556.
6. Castoria G, D'Amato L, Ciociola A, Giovannelli P, Giraldi T, Sepe L et al. Androgen-induced cell migration: role of androgen receptor/filamin A association. PLoS One 2011; 6: e17218.
7. Chen P, Gupta K, Wells A. Cell movement elicited by epidermal growth factor receptor requires kinase and autophosphorylation but is separable from mitogenesis. J Cell Biol 1994; 124: 547-555.
8. Chen P, Xie H, Sekar MC, Gupta K, Wells A. Epidermal growth factor receptor-mediated cell motility: phospholipase C activity is required, but mitogen-activated protein kinase activity is not sufficient for induced cell movement. J Cell Biol 1994; 127: 847-857.
9. Gerhardt H, Golding M, Fruttiger M, Ruhrberg C, Lundkvist A, Abramsson A et al. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol 2003; 161: 1163-1177.
10. De Donatis A, Comito G, Buricchi F, Vinci MC, Parenti A, Caselli A et al. Proliferation versus migration in platelet-derived growth factor signaling: the key role of endocytosis. J Biol Chem 2008; 283: 19948-19956.
11. Ghosh P, Beas AO, Bornheimer SJ, Garcia-Marcos M, Forry EP, Johannson C et al. A G{alpha}i-GIV molecular complex binds epidermal growth factor receptor and determines whether cells migrate or proliferate. Mol Biol Cell 2010; 21: 2338-2354.
12. Zheng Y, Zhang C, Croucher DR, Soliman MA, St-Denis N, Pasculescu A et al. Temporal regulation of EGF signalling networks by the scaffold protein Shc1. Nature 2013; 499: 166-171.
13. Geiser AG, Anderson MJ, Stanbridge EJ. Suppression of tumorigenicity in human cell hybrids derived from cell lines expressing different activated Ras oncogenes. Cancer Res 1989; 49: 1572-1577.
14. Migliaccio A, Castoria G, Di Domenico M, de Falco A, Bilancio A, Lombardi M et al. Steroid-induced androgen receptor-oestradiol receptor β-Src complex triggers prostate cancer cell proliferation. EMBO J 2000; 19: 5406-5417.
15. Sherr CJ, Roberts JM. Living with or without cyclins and cyclin-dependent kinases. Genes Dev 2004; 18: 2699-2711.
16. Hengst L, Reed SI. Translational control of p27Kip1 accumulation during the cell cycle. Science 1996; 271: 1861-1864.
17. Rodier G, Montagnoli A, Di Marcotullio L, Coulombe P, Draetta GF, Pagano M et al. p27 cytoplasmic localization is regulated by phosphorylation on Ser10 and is not a prerequisite for its proteolysis. EMBO J 2001; 20: 6672-6682.
18. Ishida N, Hara T, Kamura T, Yoshida M, Nakayama K, Nakayama KI. Phosphorylation of p27Kip1 on serine 10 is required for its binding to CRM1 and nuclear export. J Biol Chem 2002; 277: 14355-14358.
19. Deng X, Mercer SE, Shah S, Ewton DZ, Friedman E. The cyclin-dependent kinase inhibitor p27Kip1 is stabilized in G(0) by Mirk/dyrk1B kinase. J Biol Chem 2004; 279: 22498-22504.
20. Besson A, Gurian-West M, Chen X, Kelly-Spratt KS, Kemp CJ, Roberts JM. A pathway in quiescent cells that controls p27Kip1 stability, subcellular localization, and tumor suppression. Genes Dev 2006; 20: 47-64.
21. Becker W. Emerging role of DYRK family protein kinases as regulators of protein stability in cell cycle control. Cell Cycle 2012; 11: 3389-3394.
22. Ashford AL, Oxley D, Kettle J, Hudson K, Guichard S, Cook SJ et al. A novel DYRK1B inhibitor AZ191 demonstrates that DYRK1B acts independently of GSK3β to phosphorylate cyclin D1 at Thr(286), not Thr(288). Biochem J 2014; 457: 43-56.
23. Deng X, Ewton DZ, Pawlikowski B, Maimone M, Friedman E. Mirk/dyrk1B is a Rho-induced kinase active in skeletal muscle differentiation. J Biol Chem 2003; 278: 41347-41354.
24. Shutes A, Onesto C, Picard V, Leblond B, Schweighoffer F, Der CJ. Specificity and mechanism of action of EHT 1864, a novel small molecule inhibitor of Rac family small GTPases. J Biol Chem 2007; 282: 35666-35678.
25. Loy CJ, Sim KS, Yong EL. Filamin-A fragment localizes to the nucleus to regulate androgen receptor and coactivator functions. Proc Natl Acad Sci USA 2003; 100: 4562-4567.
26. Verdine GL, Hilinski GJ. Stapled peptides for intracellular drug targets. Methods Enzymol 2012; 503: 3-33.
27. Loo DT, Kanner SB, Aruffo A. Filamin binds to the cytoplasmic domain of the beta 1 integrin: identification of aminoacids responsible of this interaction. J Biol Chem 1998; 273: 23304-23312.
28. Barone MV, Courtneidge SA. Myc but not Fos rescue of PDGF signalling block caused by kinase-inactive Src. Nature 1995; 378: 509-512.
29. Rodriguez-Viciana P, Warne PH, Khwaja A, Marte BM, Pappin D, Das P et al. Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell 1997; 89: 457-467.
30. Jin K, Park S, Ewton DZ, Friedman E. The survival kinase Mirk/Dyrk1B is a downstream effector of oncogenic K-ras in pancreatic cancer. Cancer Res 2007; 1: 7247-7255.
31. Sheaff RJ, Groudine M, Gordon M, Roberts JM, Clurman BE. Cyclin E-CDK2 is a regulator of p27Kip1. Genes Dev 1997; 11: 1464-1478.
32. Sharpe RM. Pathways of endocrine disruption during male sexual differentiation and masculinization. Best Pract Res Clin Endocrinol Metab 2006; 20: 91-110.
33. Heasman SJ, Ridley AJ. Mammalian Rho GTPases: new insights into their functions from in vivo studies. Nat Rev Mol Cell Biol 2008; 9: 690-701.
34. Bektic J, Pfeil K, Berger AP, Ramoner R, Pelzer A, Schäfer G et al. Small G-protein RhoE is underexpressed in prostate cancer and induces cell cycle arrest and apoptosis. Prostate 2005; 64: 332-340.
35. Villalonga P, Guasch RM, Riento K, Ridley AJ. RhoE inhibits cell cycle progression and Ras-induced transformation. Mol Cell Biol 2004; 24: 7829-7840.
36. Lauth M, Bergström A, Shimokawa T, Tostar U, Jin Q, Fendrich V et al. DYRK1B-dependent autocrine-to-paracrine shift of Hedgehog signaling by mutant RAS. Nat Struct Mol Biol 2010; 17: 718-725.
37. Deng X, Friedman E. Mirk kinase inhibition blocks the in vivo growth of pancreatic cancer cells. Genes Cancer 2014; 5: 9-10.
38. Bos J L. Ras oncogenes in human cancer: a review. Cancer Res 1989; 49: 4682-4689.
39. Jeong Y, Xie Y, Lee W, Bookout AL, Girard L, Raso G et al. Research resource: diagnostic and therapeutic potential of nuclear receptor expression in lung cancer. Mol Endocrinol 2012; 26: 1443-1454.
40. Chang C, Lee SO, Yeh S, Chang TM. Androgen receptor (AR) differential roles in hormone-related tumors including prostate, bladder, kidney, lung, breast and liver. Oncogene 2013; 33: 3225-3234.
41. Okitsu K, Kanda T, Imazeki F, Yonemitsu Y, Ray RB, Chang C et al. Involvement of interleukin-6 and androgen receptor signaling in pancreatic cancer. Genes Cancer 2010; 1: 859-867.
42. Gu S, Papadopoulou N, Nasir O, Föller M, Alevizopoulos K, Lang F et al. Activation of membrane androgen receptors in colon cancer inhibits the prosurvival signals Akt/bad in vitro and in vivo and blocks migration via vinculin/actin signaling. Mol Med 2011; 17: 48-58.
43. Chang CS, Kokontis J, Liao ST. Structural analysis of complementary DNA and amino acid sequences of human and rat androgen receptors. Proc Natl Acad Sci USA 1988; 85: 7211-7215.
44. Verrijdt G, Schoenmakers E, Haelens A, Peeters B, Verhoeven G, Rombauts W et al. Change of specificity mutations in androgen-selective enhancers. Evidence for a role of differential DNA binding by the androgen receptor. J Biol Chem 2000; 275: 12298-12305.
45. Imle A, Polzer B, Alexander S, Klein CA, Friedl P. Genomic instability of micronucleated cells revealed by single-cell comparative genomic hybridization. Cytometry 2009; 75: 562-568.
46. Varricchio L, Migliaccio A, Castoria G, Yamaguchi H, de Falco A, Di Domenico M et al. Inhibition of estradiol receptor/Src association and cell growth by an estradiol receptor {alpha} tyrosine-phosphorylated peptide. Mol Cancer Res. 2007; 11: 1213-1221.
47. Castoria G, Giovannelli P, Lombardi M, De Rosa C, Giraldi T, de Falco A et al. Tyrosine phosphorylation of estradiol receptor by Src regulates its hormone-dependent nuclear export and cell cycle progression in breast cancer cells. Oncogene 2012; 31: 4868-4877.
48. Lombardi M, Castoria G, Migliaccio A, Barone MV, Di Stasio R, Ciociola A et al. Hormone-dependent nuclear export of estradiol receptor and DNA synthesis in breast cancer cells. J Cell Biol 2008; 182: 327-340.
49. Bernal F, Tyler AF, Korsmeyer SJ, Walensky LD, Verdine GL. Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide. J Am Chem Soc 2007; 129: 2456-2457.
50. Bernal F, Wade M, Godes M, Davis TN, Whitehead DG, Kung AL et al. A stapled p53 helix overcomes HDMX-mediated suppression of p53. Cancer Cell 2010; 18: 411-422.
51. Bird G H, Bernal F, Pitter K, Walensky LD. Synthesis and biophysical characterization of stabilized alpha-helices of BCL-2 domains. Meth Enzymol 2008; 446: 369-386.
52. Takahashi-Yanaga F, Mori J, Matsuzaki E, Watanabe Y, Hirata M, Miwa Y et al. Involvement of GSK-3beta and DYRK1B in differentiation-inducing factor-3-induced phosphorylation of cyclin D1 in HeLa cells. J Biol Chem 2006; 281: 38489-38497.